Announcements Trials
Browse Landscape

Phase

Phase 1 12Phase 3 7Phase 2 4Phase 1/2 2Phase 4 1

Status

Active not recruiting 7

Sponsor Class

OTHER 11INDUSTRY 7NETWORK 3

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 7

Conditions

Prostatic Neoplasms 6Metastatic Castrate-sensitive Prostate Cancer 1

Interventions

Carboplatin 314Paclitaxel 302Cisplatin 250Docetaxel 237pembrolizumab 230Gemcitabine 213Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 120Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 92Prednisone 91Oxaliplatin 89atezolizumab 73Leucovorin 71durvalumab 69130-nm albumin-bound paclitaxel 67Injections 64Lenalidomide 63Irinotecan 60Bortezomib 55Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × apalutamide × Clear all
NCT01946204 2026-05-11

SPARTAN

Aragon Pharmaceuticals, Inc.

Phase 3 Active not recruiting
1,207 enrolled 15 charts 1 FDA
Genitourinary

Prostatic Neoplasms

NCT02257736 2026-05-11

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Aragon Pharmaceuticals, Inc.

Phase 3 Active not recruiting
982 enrolled 15 charts
Genitourinary

Prostatic Neoplasms

NCT02489318 2026-05-11

TITAN

Aragon Pharmaceuticals, Inc.

Phase 3 Active not recruiting
1,052 enrolled 13 charts 1 FDA
Genitourinary

Prostatic Neoplasms

NCT02531516 2026-05-08

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Aragon Pharmaceuticals, Inc.

Phase 3 Active not recruiting
1,503 enrolled
Genitourinary

Prostatic Neoplasms

NCT03767244 2026-05-08

PROTEUS

Janssen Research & Development, LLC

Phase 3 Active not recruiting
2,517 enrolled
Genitourinary

Prostatic Neoplasms

NCT04557059 2026-05-08

PRIMORDIUM

Janssen Pharmaceutica N.V., Belgium

Phase 3 Active not recruiting
692 enrolled
Genitourinary

Prostatic Neoplasms

NCT05884398 2026-03-12

LIBERTAS

Janssen Research & Development, LLC

Phase 3 Active not recruiting
420 enrolled
Genitourinary

Metastatic Castrate-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡